Pinboard (aheilbut)
https://pinboard.in/u:aheilbut/public/
recent bookmarks from aheilbutFDA Panel Rejects Lilly’s Cancer Drug Tested Only in China - The New York Times2022-03-01T04:44:45+00:00
https://www.nytimes.com/2022/02/10/health/fda-cancer-drug-china.html
aheilbutchina FDA trials lilly checkpoint sintilimabhttps://pinboard.in/https://pinboard.in/u:aheilbut/b:a5655c306dd6/FDA criminal office’s approach irks some doctors, agents2022-02-23T05:01:18+00:00
https://www.reuters.com/investigates/special-report/usa-fda-cases/
aheilbutfda ocihttps://pinboard.in/https://pinboard.in/u:aheilbut/b:c647b01d8ef6/CFR - Code of Federal Regulations Title 212021-08-31T02:00:54+00:00
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=312&showFR=1&subpartNode=21:5.0.1.1.3.3
aheilbutFDA IND fraudhttps://pinboard.in/https://pinboard.in/u:aheilbut/b:64ae34a1c666/Eight charged in scheme to defraud FDA and falsify records used in clinical research trials | USAO-NDOH | Department of Justice2021-04-03T23:06:28+00:00
https://www.justice.gov/usao-ndoh/pr/eight-charged-scheme-defraud-fda-and-falsify-records-used-clinical-research-trials
aheilbutFDA fraudhttps://pinboard.in/https://pinboard.in/u:aheilbut/b:8c855ab370ed/Ogden Nash’s Rule of Thumb Ignored: Group of 8 Face Criminal Indictment for Falsifying Clinical Trial Records2021-04-03T23:06:08+00:00
https://www.fdalawblog.net/2020/08/ogden-nashs-rule-of-thumb-ignored-group-of-8-face-criminal-indictment-for-falsifying-clinical-trial-records/
aheilbutFDA fraud clinicaltrialshttps://pinboard.in/https://pinboard.in/u:aheilbut/b:0d773006260b/PhillyCooke Consulting2021-01-05T18:07:56+00:00
https://regulatoryrx.blogspot.com/
aheilbutFDAhttps://pinboard.in/https://pinboard.in/u:aheilbut/b:f26851b0940d/When FDA and the Practice of (Tele)Medicine Collide2021-01-05T13:04:49+00:00
https://www.fdalawblog.net/2019/10/when-fda-and-the-practice-of-telemedicine-collide/
aheilbutFDAhttps://pinboard.in/https://pinboard.in/u:aheilbut/b:ca400f8a5363/In Vitro Diagnostics EUAs | FDA2020-08-25T21:44:31+00:00
https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/vitro-diagnostics-euas
aheilbutFDA diagnostics COVID EUAhttps://pinboard.in/https://pinboard.in/u:aheilbut/b:269ca25c26d8/FDA Drug Approvals Are Faster But Rely On Less Evidence Than They Used To : Shots - Health News : NPR2020-01-16T17:52:50+00:00
https://www.npr.org/sections/health-shots/2020/01/14/796227083/fda-approves-drugs-faster-than-ever-but-relies-on-weaker-evidence-researchers-fi
aheilbutFDAhttps://pinboard.in/https://pinboard.in/u:aheilbut/b:156236b133eb/[untitled]2019-09-10T20:08:21+00:00
https://www.fda.gov/media/72710/download
aheilbutPDUFA FDAhttps://pinboard.in/https://pinboard.in/u:aheilbut/b:8a00c7d70ddb/Promotion of Investigational Compound – Historical Overview | Eye on FDA2019-07-15T18:20:21+00:00
http://eyeonfda.com/2016/03/promotion-of-investigational-compound-historical-overview/
aheilbutFDA promotion INDhttps://pinboard.in/https://pinboard.in/u:aheilbut/b:ee5f72d309df/FDA In Brief: FDA seeks public feedback on new drug approval transparency efforts | FDA2019-06-26T18:06:56+00:00
https://www.fda.gov/news-events/fda-brief/fda-brief-fda-seeks-public-feedback-new-drug-approval-transparency-efforts
aheilbutFDA transparencyhttps://pinboard.in/https://pinboard.in/u:aheilbut/b:42caf48d6a5f/Three Statistics Every ANDA Filer Needs To Know About Orange Book Patent Trials At the USPTO | Knobbe Martens Intellectual Property Law2019-06-26T17:05:01+00:00
https://www.knobbe.com/news/2018/03/three-statistics-every-anda-filer-needs-know-about-orange-book-patent-trials-uspto
aheilbutorangebook FDA ANDAhttps://pinboard.in/https://pinboard.in/u:aheilbut/b:33e33262983f/SAC Tracker2019-06-21T17:22:39+00:00
http://www.sac-tracker.com/
aheilbutFDA regulatoryhttps://pinboard.in/https://pinboard.in/u:aheilbut/b:bfeaa1f52f09/Judge Says FDA Can Stop Clinic from Selling Stem Cell Treatments | The Scientist Magazine®2019-06-10T17:30:55+00:00
https://www.the-scientist.com/news-opinion/judge-says-fda-can-stop-clinic-from-selling-stem-cell-treatments-65989?_hsenc=p2ANqtz--IQc728MJPj5-4Kdi97KpROKkZafkGhXDSHy4P1Lb2S9uB6rAACq97GkkeYf8BzyA8PhFpG77AEUVgW9ytxC8_LeZMzA&_hsmi=73514226
aheilbutfda stemcellhttps://pinboard.in/https://pinboard.in/u:aheilbut/b:0e6c760e9371/Science and Regulation of Live Microbiome-Based Products Used to Prevent, Treat, or Cure Diseases in Humans - 09/17/2018 - 09/17/2018 | FDA2019-05-30T20:57:41+00:00
https://www.fda.gov/vaccines-blood-biologics/workshops-meetings-conferences-biologics/science-and-regulation-live-microbiome-based-products-used-prevent-treat-or-cure-diseases-humans
aheilbutmicrobiome drugs FDAhttps://pinboard.in/https://pinboard.in/u:aheilbut/b:3583077cd706/FDA Fast Track and Priority Review Programs - EveryCRSReport.com2019-05-24T15:21:51+00:00
https://www.everycrsreport.com/reports/RS22814.html#_Toc257797172
aheilbutfdahttps://pinboard.in/https://pinboard.in/u:aheilbut/b:387ecc33041e/The Birth-Tissue Profiteers | The New Yorker2019-05-07T15:57:21+00:00
https://www.newyorker.com/news/news-desk/the-birth-tissue-profiteers
aheilbutamniotic stemcell FDAhttps://pinboard.in/https://pinboard.in/u:aheilbut/b:14354137c236/Polygenic risk score based on weight gain trajectories is a strong predictor of childhood obesity | bioRxiv2019-04-18T16:44:50+00:00
https://www.biorxiv.org/content/10.1101/606277v1.full
aheilbutobesity gwas functional FDAhttps://pinboard.in/https://pinboard.in/u:aheilbut/b:94d3b9154419/Perspectives: FDA warns umbilical firm & continues stream of "mini-warning" letters - The Niche2019-04-12T17:10:31+00:00
https://ipscell.com/2019/04/perspectives-fda-warns-umbilical-firm-continues-stream-of-mini-warning-letters/
aheilbutFDA safetyhttps://pinboard.in/https://pinboard.in/u:aheilbut/b:c3f45c75c140/Patent Baristas » Three-Year Market Exclusivity Extension for a New Indication of a Drug2019-04-10T20:22:07+00:00
http://www.patentbaristas.com/archives/2006/03/07/three-year-market-exclusivity-extension-for-a-new-indication-of-a-drug/
aheilbutFDA exclusivityhttps://pinboard.in/https://pinboard.in/u:aheilbut/b:7d9fdc1b72b6/FDA Revises Guidance on Special Protocol Assessments, Attempts to Reduce Uncertainty2019-04-02T21:20:17+00:00
http://www.fdalawblog.net/2016/05/fda-revises-guidance-on-special-protocol-assessments-attempts-to-reduce-uncertainty/
aheilbutFDA SPA Amarin ANCHORhttps://pinboard.in/https://pinboard.in/u:aheilbut/b:cac617dce8e1/FDA Grants Priority Review For Amgen's sBLA For Repatha - American College of Cardiology2019-03-29T15:50:42+00:00
https://www.acc.org/latest-in-cardiology/articles/2017/08/07/10/41/fda-grants-priority-review-for-amgens-sbla-for-repatha
aheilbutAMRN PCSK9 priority FDAhttps://pinboard.in/https://pinboard.in/u:aheilbut/b:7c8836c94d69/Press Announcements > Remarks from FDA Commissioner Scott Gottlieb, M.D., as prepared for testimony before a U.S. Senate Subcommittee on Appropriations on FDA’s Fiscal Year 2020 budget2019-03-28T20:14:15+00:00
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm634648.htm
aheilbutFDA opioids comparativehttps://pinboard.in/https://pinboard.in/u:aheilbut/b:3158caad2fb3/[untitled]2019-03-11T21:58:10+00:00
https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm073137.pdf
aheilbutFDA clinicalhttps://pinboard.in/https://pinboard.in/u:aheilbut/b:cbb47654c3c2/F.D.A. Nominee, Paid Millions by Industry, Says He’ll Recuse Himself if Needed - The New York Times2019-03-06T18:34:49+00:00
https://www.nytimes.com/2017/03/29/health/fda-nominee-scott-gottlieb-recuse-conflicts.html
aheilbutgottlieb FDA conflictshttps://pinboard.in/https://pinboard.in/u:aheilbut/b:84e8244a05f7/Celgene to Acquire Impact Biomedicines, Adding Fedratinib to Its Pipeline of Novel Therapies for Hematologic Malignancies | Celgene Corporation2019-03-05T18:34:24+00:00
https://ir.celgene.com/press-releases/press-release-details/2018/Celgene-to-Acquire-Impact-Biomedicines-Adding-Fedratinib-to-Its-Pipeline-of-Novel-Therapies-for-Hematologic-Malignancies/default.aspx
aheilbutcelgene drugdevelopment FDA errorshttps://pinboard.in/https://pinboard.in/u:aheilbut/b:f187539065a6/[untitled]2019-02-22T20:19:09+00:00
https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM631424.pdf
aheilbutfda obesityhttps://pinboard.in/https://pinboard.in/u:aheilbut/b:26e0f1dfdf19/Amarin GC Joseph Kennedy Knows Thrill of Victory, and Saving Lives | Corporate Counsel2019-01-15T01:02:27+00:00
https://www.law.com/corpcounsel/2019/01/14/amarin-gc-joseph-kennedy-knows-thrill-of-victory-and-saving-lives/?slreturn=20190014200114
aheilbutAMRN legal FDA FDAlawhttps://pinboard.in/https://pinboard.in/u:aheilbut/b:0315d8b4df5e/Notes from the Field: Infections After Receipt of Bacterially Contaminated Umbilical Cord Blood–Derived Stem Cell Products for Other Than Hematopoietic or Immunologic Reconstitution — United States, 2018 | MMWR2018-12-20T20:11:13+00:00
https://www.cdc.gov/mmwr/volumes/67/wr/mm6750a5.htm?s_cid=mm6750a5_w
aheilbutstemcells FDA CDC infectionhttps://pinboard.in/https://pinboard.in/u:aheilbut/b:2471d07cbc73/Press Announcements > FDA sends warning to company for marketing dangerous unapproved stem cell products that put patients at risk and puts other stem cell firms, providers on notice2018-12-20T18:01:23+00:00
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm628918.htm
aheilbutFDAhttps://pinboard.in/https://pinboard.in/u:aheilbut/b:e58fc9520d45/FDA Is Evolving on Qualifications for 'New Chemical Entity'2018-11-20T19:02:22+00:00
https://www.pepperlaw.com/publications/fda-is-evolving-on-qualifications-for-new-chemical-entity-2016-09-07/
aheilbutFDA NCE exclusivityhttps://pinboard.in/https://pinboard.in/u:aheilbut/b:732771b20880/It’s Finally Here! FDA’s VASCEPA Exclusivity Determination on Remand: NCE Exclusivity Granted!2018-11-14T17:24:06+00:00
http://www.fdalawblog.net/2016/05/its-finally-here-fdas-vascepa-exclusivity-determination-on-remand-nce-exclusivity-granted/
aheilbutvascepa FDA exclusivityhttps://pinboard.in/https://pinboard.in/u:aheilbut/b:9ece814b51aa/Warning Letters > StemGenex Biologic Laboratories, LLC 10/31/182018-11-13T19:00:51+00:00
https://www.fda.gov/ICECI/EnforcementActions/WarningLetters/ucm625497.htm
aheilbutstemcells FDAhttps://pinboard.in/https://pinboard.in/u:aheilbut/b:d0c911cf6c7f/Press Announcements > Statement from FDA Commissioner Scott Gottlieb, M.D. on FDA’s efforts to strengthen the agency’s medical device cybersecurity program as part of its mission to protect patients2018-10-01T19:15:21+00:00
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/UCM622074.htm
aheilbutfda security cyberhttps://pinboard.in/https://pinboard.in/u:aheilbut/b:8abbb0aafae8/SkinTE and the FDA's 361 Pathway — Ozgur Ogut2018-07-23T16:19:08+00:00
https://www.ozgurogut.com/thoughts/2018/7/19/skinte-and-the-361-pathway
aheilbutCOOL polarityTE FDA 361https://pinboard.in/https://pinboard.in/u:aheilbut/b:d0f999c6b4eb/Mandatory Reporting Requirements: Manufacturers, Importers and Device User Facilities > Manufacturer and User Facility Device Experience Database - (MAUDE)2018-06-15T17:32:26+00:00
https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/PostmarketRequirements/ReportingAdverseEvents/ucm127891.htm
aheilbutFDA safetyhttps://pinboard.in/https://pinboard.in/u:aheilbut/b:4a237bbe16fe/FDA Adverse Event Reporting System (FAERS) > FDA Adverse Event Reporting System (FAERS): Latest Quarterly Data Files2018-06-15T17:32:06+00:00
https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/ucm082193.htm
aheilbutFDA safety adversehttps://pinboard.in/https://pinboard.in/u:aheilbut/b:a56e9a6ad133/Safety & Availability (Biologics) > 2018 Safety and Availability Communications2018-05-14T17:28:07+00:00
https://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/ucm594350.htm
aheilbutfda biologics safetyhttps://pinboard.in/https://pinboard.in/u:aheilbut/b:7036a133c8fe/Untitled Letters (Biologics) > BIMO/Team Biologics/Internet Surveillance/Other2018-05-14T17:27:47+00:00
https://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/ComplianceActivities/Enforcement/UntitledLetters/ucm091547.htm
aheilbutbiologics FDA regulation untitledlettershttps://pinboard.in/https://pinboard.in/u:aheilbut/b:28af5d20d70f/Inspection References > Inspections Database2018-05-07T22:34:51+00:00
https://www.fda.gov/ICECI/Inspections/ucm222557.htm
aheilbutFDA inspections datahttps://pinboard.in/https://pinboard.in/u:aheilbut/b:fe49aac89c90/FDA chief hints at changes to drug rebates ahead of Trump speech | TheHill2018-05-03T18:33:56+00:00
http://thehill.com/policy/healthcare/medical-devices-and-prescription-drug-policy/386068-fda-chief-hints-at-changes-to
aheilbutfdahttps://pinboard.in/https://pinboard.in/u:aheilbut/b:6730b0e0db65/Speeches by FDA Officials > Keynote Addresss by Commissioner Gottlieb to the 2018 FDLI Annual Conference2018-05-03T14:43:58+00:00
https://www.fda.gov/NewsEvents/Speeches/ucm606541.htm
aheilbutFDA policyhttps://pinboard.in/https://pinboard.in/u:aheilbut/b:3ebcb9b5f026/Increased FDA Scrutiny Of Pre-Approval Communications Continued in 2012 | Insights | Sidley Austin LLP2018-05-02T16:36:58+00:00
https://www.sidley.com/en/insights/newsupdates/2013/02/increased-fda-scrutiny-of-preapproval-communications-continued-in-2012
aheilbutFDA preapprovalhttps://pinboard.in/https://pinboard.in/u:aheilbut/b:8fe6e4644141/Criminal Investigations > Press Releases2018-05-02T15:29:10+00:00
https://www.fda.gov/ICECI/CriminalInvestigations/ucm123086.htm
aheilbutFDA criminalhttps://pinboard.in/https://pinboard.in/u:aheilbut/b:c3f87435cf35/[untitled]2018-04-20T22:15:56+00:00
https://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM341008.pdf
aheilbutfda coihttps://pinboard.in/https://pinboard.in/u:aheilbut/b:c61a4873a9da/FDAzilla | The Leading Platform for GMP Inspection Analytics2018-03-29T00:34:14+00:00
https://fdazilla.com/
aheilbutFDA inspections 483 FOIA databasehttps://pinboard.in/https://pinboard.in/u:aheilbut/b:1f6c524203e7/[untitled]2018-03-28T20:10:31+00:00
https://www.fdli.org/wp-content/uploads/2017/12/Malarkey.pdf
aheilbutFDAhttps://pinboard.in/https://pinboard.in/u:aheilbut/b:6156f3a31352/[untitled]2018-03-18T17:41:33+00:00
https://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/UCM585403.pdf
aheilbutfdahttps://pinboard.in/https://pinboard.in/u:aheilbut/b:8a7824448b72/HUMAN CELL AND TISSUE ESTABLISHMENT REGISTRATION (HCTERS) - Public Query2018-02-06T08:20:39+00:00
https://www.accessdata.fda.gov/scripts/cber/CFAppsPub/tiss/index.cfm
aheilbutFDAhttps://pinboard.in/https://pinboard.in/u:aheilbut/b:3585279f9f61/Time to bone up on 'homologous use' in the stem cell field - The Niche2018-01-21T03:36:25+00:00
https://ipscell.com/2013/07/time-to-bone-up-on-homologous-use-in-the-stem-cell-field/
aheilbutFDA homolgoushttps://pinboard.in/https://pinboard.in/u:aheilbut/b:6218016836e2/‘The Trump Of Georgia’ Goes To Washington | Kaiser Health News2018-01-13T16:37:50+00:00
https://khn.org/news/the-trump-of-georgia-goes-to-washington/
aheilbutmdxg FDAhttps://pinboard.in/https://pinboard.in/u:aheilbut/b:9af5400ee6c9/WITHDRAWN: A Resource for Withdrawn and Discontinued Drugs2017-09-26T20:49:26+00:00
http://cheminfo.charite.de/withdrawn/
aheilbutdatabase pharmacology FDAhttps://pinboard.in/https://pinboard.in/u:aheilbut/b:5e5c302de4d9/JAMA Network | JAMA Internal Medicine | Research Misconduct Identified by the US Food and Drug Administration: Out of Sight, Out of Mind, Out of the Peer-Reviewed Literature2015-02-14T00:29:55+00:00
http://archinte.jamanetwork.com/article.aspx?articleid=2109855#ioi140141r67
aheilbutfda fraud misconducthttps://pinboard.in/https://pinboard.in/u:aheilbut/b:7b4da3e816c2/Guidances2015-01-06T18:13:32+00:00
http://www.fda.gov/RegulatoryInformation/Guidances/default.htm
aheilbutfdahttps://pinboard.in/https://pinboard.in/u:aheilbut/b:8a4ddc346012/Home | openFDA2014-06-03T02:52:41+00:00
http://open.fda.gov/
aheilbutfda datahttps://pinboard.in/https://pinboard.in/u:aheilbut/b:91fe1d01862a/Press Announcements > FDA launches openFDA to provide easy access to valuable FDA public data2014-06-03T02:52:28+00:00
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm399335.htm?source=govdelivery
aheilbutfda datahttps://pinboard.in/https://pinboard.in/u:aheilbut/b:414555c5cd44/A Drug Recall That Should Frighten Us All About The FDA2014-04-28T04:56:20+00:00
http://www.forbes.com/sites/davidmaris/2012/10/10/fda-recall-points-to-serious-problems-at-the-fda/2/
aheilbutfda bioequivalencehttps://pinboard.in/https://pinboard.in/u:aheilbut/b:a3c95f508a17/Dirty medicine - Fortune Features2013-05-16T03:14:30+00:00
http://features.blogs.fortune.cnn.com/2013/05/15/ranbaxy-fraud-lipitor/
aheilbutranbaxy fraud pharma malfeasance trust fdahttps://pinboard.in/https://pinboard.in/u:aheilbut/b:77717f19b67c/Drug Makers Share Data From Failed Trials - WSJ.com2010-06-13T01:22:55+00:00
http://online.wsj.com/article/SB10001424052748703627704575298783153884208.html?mod=igoogle_wsj_gadgv1&#articleTabs_comments
aheilbutpharma collaboration transparency fdahttps://pinboard.in/u:aheilbut/b:cc99f0beace8/Phase II Transparency Report: Draft Proposals2010-05-21T03:05:57+00:00
http://www.fda.gov/AboutFDA/WhatWeDo/FDATransparencyTaskForce/TransparencyReport/default.htm
aheilbutfda transparencyhttps://pinboard.in/u:aheilbut/b:04c4bad45c1a/PRS Information: U.S. Public Law 110-852009-04-21T04:45:35+00:00
http://prsinfo.clinicaltrials.gov/public-meeting-april09.html
aheilbutfdaaa fda clinicaltrials transparencyhttps://pinboard.in/u:aheilbut/b:d2279a43766c/What the FDA isn't telling. - By Jeanne Lenzer - Slate Magazine2009-03-15T22:47:12+00:00
http://www.slate.com/id/2126918/
aheilbuttransparency fda clinicaltrialshttps://pinboard.in/u:aheilbut/b:a2ca899d8cc9/Update on Clinical Trials Registration and Results Reporting Requirements; and Methodologic Issues and Next Steps in the Implementation of the Results Database - CHP/PCOR2009-03-15T22:36:38+00:00
http://healthpolicy.stanford.edu/events/update_on_clinical_trials_registration_and_results_reporting_requirements_and_methodologic_issues_and_next_steps_in_the_implementation_of_the_results_database/
aheilbutclinicaltrials transparency fda zarin clinicaltrials.govhttps://pinboard.in/u:aheilbut/b:addbd573cf61/Drug Makers Near an Old Goal: A Legal Shield - New York Times2008-04-05T18:12:56+00:00
http://www.nytimes.com/2008/04/06/washington/06patch.html?hp=&adxnnl=1&adxnnlx=1207418869-dqkmIofYFS2g7fz6eZZmjg
aheilbutjnj patch preemption law risk fdahttps://pinboard.in/u:aheilbut/b:e6135846d3d4/Fixing the Drug Laws -- Kennedy 316 (5832): 1669 -- Science2007-06-28T18:54:37+00:00
http://www.sciencemag.org/cgi/content/full/316/5832/1669
aheilbuttransparency fda legislationhttps://pinboard.in/u:aheilbut/b:670e91115b06/Orange Book Blog2007-05-17T15:05:43+00:00
http://www.orangebookblog.com/
aheilbutbiotech law fda bloghttps://pinboard.in/u:aheilbut/b:60723d5d89e9/Eye on FDA2006-06-04T02:33:36+00:00
http://www.eyeonfda.com/
aheilbutblog law bigpharma fdahttps://pinboard.in/u:aheilbut/b:a764806623e4/